These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 29305554)

  • 21. Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports.
    Padmore R
    Transfusion; 2015 Jul; 55 Suppl 2():S59-64. PubMed ID: 26174898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specifications for anti-A and anti-B in intravenous immunoglobulin: history and rationale.
    Thorpe SJ
    Transfusion; 2015 Jul; 55 Suppl 2():S80-5. PubMed ID: 26174902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemolysis from ABO Incompatibility.
    Simmons DP; Savage WJ
    Hematol Oncol Clin North Am; 2015 Jun; 29(3):429-43. PubMed ID: 26043383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safeguarding immune globulin recipients against hemolysis: what do we know and where do we go?
    Scott DE; Epstein JS
    Transfusion; 2015 Jul; 55 Suppl 2():S122-6. PubMed ID: 26174890
    [No Abstract]   [Full Text] [Related]  

  • 25. Anti-A and anti-B: what are they and where do they come from?
    Branch DR
    Transfusion; 2015 Jul; 55 Suppl 2():S74-9. PubMed ID: 26174901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy and safety of intravenous immunoglobulins in the management of neonatal hyperbilirubinemia due to ABO incompatibility: a meta-analysis].
    Cortey A; Elzaabi M; Waegemans T; Roch B; Aujard Y
    Arch Pediatr; 2014 Sep; 21(9):976-83. PubMed ID: 25125032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemolysis upon intravenous immunoglobulin transfusion.
    Padmore RF
    Transfus Apher Sci; 2012 Feb; 46(1):93-6. PubMed ID: 22169381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune hemolysis following ABO-mismatched stem cell or solid organ transplantation.
    Yazer MH; Triulzi DJ
    Curr Opin Hematol; 2007 Nov; 14(6):664-70. PubMed ID: 17898572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ABO-histo blood group incompatibility in hematopoietic stem cell and solid organ transplantation.
    Stussi G; Halter J; Schanz U; Seebach JD
    Transfus Apher Sci; 2006 Aug; 35(1):59-69. PubMed ID: 16935028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies.
    Josephson CD; Castillejo MI; Grima K; Hillyer CD
    Transfus Apher Sci; 2010 Feb; 42(1):83-8. PubMed ID: 20034854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and risk factors for intravenous immunoglobulin-related hemolysis: A systematic review of clinical trial and real-world populations.
    Cuesta H; El Menyawi I; Hubsch A; Hoefferer L; Mielke O; Gabriel S; Shebl A
    Transfusion; 2022 Sep; 62(9):1894-1907. PubMed ID: 35916266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral administration of Chinese herbal medicine during gestation period for preventing hemolytic disease of the newborn due to ABO incompatibility: A systematic review of randomized controlled trials.
    Cao H; Wu R; Han M; Caldwell PHY; Liu JP
    PLoS One; 2017; 12(7):e0180746. PubMed ID: 28719639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients.
    Jordan SC; Peng A; Vo AA
    Contrib Nephrol; 2009; 162():13-26. PubMed ID: 19001810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current progress in ABO-incompatible liver transplantation.
    Tanabe M; Kawachi S; Obara H; Shinoda M; Hibi T; Kitagawa Y; Wakabayashi G; Shimazu M; Kitajima M
    Eur J Clin Invest; 2010 Oct; 40(10):943-9. PubMed ID: 20636381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulating alloimmune responses with plasmapheresis and IVIG.
    Warren DS; Simpkins CE; Cooper M; Montgomery RA
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Jun; 5(3):215-22. PubMed ID: 15975035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ABO and platelet transfusion therapy.
    Cooling L
    Immunohematology; 2007; 23(1):20-33. PubMed ID: 17425412
    [No Abstract]   [Full Text] [Related]  

  • 37. Do immune complexes play a role in hemolytic sequelae of intravenous immune globulin?
    Zimring JC
    Transfusion; 2015 Jul; 55 Suppl 2():S86-9. PubMed ID: 26174903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytokines as intercellular signals in hemolytic transfusion reactions.
    Davenport RD
    Biol Signals; 1996; 5(4):240-5. PubMed ID: 8891200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathogenesis and mechanisms of antibody-mediated hemolysis.
    Flegel WA
    Transfusion; 2015 Jul; 55 Suppl 2(0):S47-58. PubMed ID: 26174897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ABO zygosity, but not secretor or Fc receptor status, is a significant risk factor for IVIG-associated hemolysis.
    Branch DR; Hellberg Å; Bruggeman CW; Storry JR; Sakac D; Blacquiere M; Tong TN; Burke-Murphy E; Binnington B; Parmar N; Riden LS; Willie K; Armali C; Aziz J; Lieberman L; Laroche V; Callum J; Lin Y; Shehata N; Pavenski K; Lau W; Hannach B; Kuijpers TW; Olsson ML; Cserti-Gazdewich C; Pendergrast J
    Blood; 2018 Feb; 131(7):830-835. PubMed ID: 29305554
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.